Among the many stents, surgical clamps, pumps and other medical devices that have recently come before the Food and Drug Administration for clearance, none has excited the widespread hopes of physicians and researchers like a machine called the Illumina MiSeqDx.<\/p>\n
This compact DNA sequencer has the potential to change the way doctors care for patients by making personalized medicine a reality, experts say. <\/p>\n
\"It's about time,\" said Michael Snyder, director of the Stanford Center for Genomics and Personalized Medicine. <\/p>\n
Physicians who rely on genetic tests to guide their patients' treatment have had to order scans that reveal only small parts of a patient's genome, as if peeking through a keyhole, Snyder said: \"Why would you study just a few genes when you can see the whole thing?\" <\/p>\n
Back in 2000, when the Human Genome Project completed its first draft of the 3 billion base pairs that make up a person's DNA, the effort took a full decade and cost close to $100 million. The Illumina MiSeqDx can pull off the same feat in about a day for less than $5,000 and the results will be more accurate, two of the nation's top physicians gushed in the New England Journal of Medicine. <\/p>\n
That confluence of \"faster, cheaper and better\" is likely to accelerate the use of genetic information in everyday medical care, Dr. Francis Collins, director of the National Institutes of Health, and Dr. Margaret Hamburg, commissioner of the FDA, wrote last month. DNA sequencing should guide physicians in choosing the best drug to treat a specific patient for a specific disease while risking the fewest side effects. <\/p>\n
The Illumina MiSeqDx platform works by breaking down, rebuilding and recording the entire sequence of a person's DNA in a massively parallel fashion, completing the job in a matter of hours. The company intends to market the machine to diagnostic labs, medical centers and private practices, at a price slightly more than $125,000. <\/p>\n
Now that MiSeqDx has been approved, several other whole-genome sequencers are likely to seek the FDA's blessing in the coming months, agency officials say. <\/p>\n
Right away, the technology is poised to improve the diagnosis and treatment of cystic fibrosis. Two new assays for the chronic lung condition both developed by Illumina for use on the MiSeqDx were approved in November by the FDA. Instead of checking for the six mutations most commonly linked to the disease, the new tests are able to discern a total of 139 genetic variations that give rise to cystic fibrosis. They will also tell doctors whether a patient is among the 4% who has a mutation that's targeted by a specific, costly drug. <\/p>\n
Whole-genome sequencing has begun to reshape the way physicians diagnose and treat cancer as well. For a growing number of patients, treatment is guided by a DNA scan that reveals which mutation gave rise to the malignancy, not the organ in which the cancer manifests itself. <\/p>\n
<\/p>\n
Read more from the original source: Among the many stents, surgical clamps, pumps and other medical devices that have recently come before the Food and Drug Administration for clearance, none has excited the widespread hopes of physicians and researchers like a machine called the Illumina MiSeqDx. This compact DNA sequencer has the potential to change the way doctors care for patients by making personalized medicine a reality, experts say. \"It's about time,\" said Michael Snyder, director of the Stanford Center for Genomics and Personalized Medicine. Continue reading
\nDNA sequencer raises doctors' hopes for personalized medicine<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"